Actively Recruiting
Evaluating RAP-219 Tablets for Reducing Focal Seizures in Adults Randomized, Double-blind, Placebo-controlled Phase 3 Study
Led by Rapport Therapeutics Inc. · Updated on 2026-10-26
333
Participants Needed
18
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the investigational drug RAP-219 in adults with focal seizures to determine its safety and effectiveness in reducing the frequency of these seizures. This Phase 3 study involves participants diagnosed with focal epilepsy, aiming to compare different doses of RAP-219 against a placebo. The study is designed as a randomized, double-blind, placebo-controlled trial to rigorously assess treatment outcomes. Participants will be randomly assigned to one of three groups high dose RAP-219, medium dose RAP-219, or placebo, all given as daily oral tablets. After completing the 14-week double-blind treatment period, participants may join an open-label extension study for long-term safety monitoring or enter an 8-week post-treatment follow-up period. This structure helps assess both immediate and ongoing effects of the drug. During the trial, participants will keep daily seizure records using an electronic diary to track focal seizure activity. Researchers will monitor seizure frequency changes from baseline to the end of treatment, focusing on median percent change and responder rates with at least 50% reduction. Additional assessments include seizure-free intervals and safety evaluations throughout the study and follow-up periods, lasting until study completion in 2029.
CONDITIONS
Brief Title
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Research Team
R
Rapport Medical
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here